News

It is certainly a good Dividend King to buy in September.

The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.

Johnson & Johnson (NYSE:JNJ) reported new clinical trial results for RYBREVANT-based regimens in EGFR-mutated NSCLC at a major oncology conference. The Phase 2b COPERNICUS study showed RYBREVANT plus LAZCLUZE for newly diagnosed patients with EGFR-mutated NSCLC had improved tolerability and fewer treatment-related adverse events. Final data from the Phase 3 PAPILLON trial found first-line RYBREVANT plus chemotherapy produced the longest reported median overall survival in EGFR exon 20...

A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.

Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.

Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.

Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction […]

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Retirees don’t need the highest yield on the board. They need the check to keep arriving, and to keep growing, through every recession, rate cycle, and regime change. Three Dividend Kings fit that brief: Coca-Cola, Johnson & Johnson, and PepsiCo. Each has raised its payout for decades without a cut, and one benchmark says it […]

AI safety warnings sent tech stocks lower Monday, pushing investors into J&J, Eli Lilly, Kimberly-Clark, and Costco.

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder.

Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.

Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.

Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline programs to support accelerating growth through the end of the decade. Speaking at a Morgan Stanley e

These alleged talks come as J&J considers what direction to take DePuy Synthes in as it spins out from the wider business.

Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.

A Roth IRA turns every dividend into a tax shield: qualified distributions in retirement escape federal income tax entirely, and reinvested payouts compound without a drag from Uncle Sam. That advantage is especially potent for REIT distributions, which are typically taxed as ordinary income in a taxable account. The five blue chips below combine long […]

Apollo is in discussions to acquire DePuy Synthes, which generated $9.3 billion in sales last year and could also be spun off as a public company

PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.

Johnson & Johnson (NYSE:JNJ) shares rose 1. 3% to $268.

Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR

(Corrects the oil price percentage change in the sixth paragraph.) US equity futures were edging

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Your Medicare premium leaves your Social Security check before you ever see it, but the right dividend portfolio changes that equation permanently. The tricky part is knowing exactly how much capital your specific income bracket demands.

Johnson & Johnson, Coca-Cola and Exxon Mobil have been highlighted in this Investment Ideas article.